Table 1.
Helminth vaccines in human clinical trials.
| Target Antigen | Adjuvant | Doses | Pathogen | Phase | Ref |
|---|---|---|---|---|---|
| Glutathione-s-transferase (Na-GST-1) | Alhydrogel | 3 | Hookworm | 1; complete | (187–190) |
| Alhydrogel + CpG | |||||
| Alhydrogel + GLA-AF | |||||
| Aspartic protease (Na-APR-1) | Alhydrogel | 3 | Hookworm | 1; complete | (191) |
| Alhydrogel + GLA-AF | |||||
| Na-GST-1 + Na-APR-1 | Alhydrogel + GLA-AF | 3 | Hookworm | 1; complete | (192, 193) |
| L3 larvae | 3 | Hookworm | N/A; complete | (194) | |
| Ancyclostoma-secreted protein (Na-ASP-2) | Alhydrogel | 3 | Hookworm | 1; complete and halted | (195–198) |
| Glutathione-s-transferase (Sh28GST) | Alhydrogel | 4 | Schistosoma haematobium | 3; complete | (199, 200) |
| Alum | 2,3 | 1; complete | (201, 202) | ||
| Sm14 | GLA-SE | 3 | Schistosoma mansoni | 2/3; ongoing | (203) |
| 2; complete | (204, 205) | ||||
| 1; complete | (206, 207) | ||||
| Tetraspanin (Sm-TSP-2) | Alhydrogel | 3 | Schistosoma mansoni | 1/2; recruiting | (208) |
| Alhydrogel + AP 10-701 | 1; complete | (209) | |||
| Alhydrogel + GLA/AF | 1; complete | (210, 211) |